Last year, Technology Review ran a story about a remotely controlled biopsy needle that doctors can operate while a patient is inside a CT machine (“Robotic Biopsy”).
Doctors use biopsy needles to grab a sample of patients’ tumors. Although this process is guided by CT scans, using current techniques, doctors cannot see the needle’s location relative to the tumor (as well as fragile tissues such as the lining of the lungs) and manipulate the needle at the same time because of radiation from the CT machine. The current technique, with all its guesswork, is time-consuming and can be risky.
The robotic biopsy machine, or “robopsy,” as it’s called, allows doctors to monitor and control the needle’s progress on a laptop displaying real-time CT images.
Its inventors say it should enable doctors to quickly grab samples of tumors in the lung, breast, and other areas of the body with less risk of serious complications, such as punctured lungs.
So far, robopsy has been tested on an artificial lung and turkey carcasses. Next month, the MIT and University of Cambridge graduate students who developed the technology will begin tests on live animals, as the first step toward FDA approval.
If robopsy is proven safe in humans and animals, it could save thousands of patients from complications related to biopsies. – By Katherine Bourzac
How AI is reinventing what computers are
Three key ways artificial intelligence is changing what it means to compute.
These weird virtual creatures evolve their bodies to solve problems
They show how intelligence and body plans are closely linked—and could unlock AI for robots.
A horrifying new AI app swaps women into porn videos with a click
Deepfake researchers have long feared the day this would arrive.
Surgeons have successfully tested a pig’s kidney in a human patient
The test, in a brain-dead patient, was very short but represents a milestone in the long quest to use animal organs in human transplants.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.